**Introduction References**

[1] Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. *Circ Res.*2014;114:1959–75. doi: 10.1161/CIRCRESAHA.114.302782. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144436/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/24902978)] [[CrossRef](https://doi.org/10.1161%2FCIRCRESAHA.114.302782" \t "_blank)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circ+Res&title=Global+perspective+on+acute+coronary+syndrome:+a+burden+on+the+young+and+poor&author=R+Vedanthan&author=B+Seligman&author=V+Fuster&volume=114&publication_year=2014&pages=1959-75&pmid=24902978&doi=10.1161/CIRCRESAHA.114.302782&)]

[2] Olvera Lopez E, Ballard BD, Jan A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 11, 2021. Cardiovascular Disease. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30571040)]

[3] BD Mortality Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.**Lancet**. 2015; *385*:117–71.[Crossref](https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_3_2_2&dbid=16&doi=10.1161%2FCIRCRESAHA.115.307937&key=10.1016%2FS0140-6736%2814%2961682-2)[Medline](https://www.ahajournals.org/servlet/linkout?suffix=e_1_3_3_2_2&dbid=8&doi=10.1161%2FCIRCRESAHA.115.307937&key=25530442)[Google Scholar](http://scholar.google.com/scholar?hl=en&q=GBD+Mortality+Causes+of+Death+Collaborators.+Global%2C+regional%2C+and+national+age-sex+specific+all-cause+and+cause-specific+mortality+for+240+causes+of+death%2C+1990%E2%80%932013%3A+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2013.Lancet.+2015%3B385%3A117%E2%80%9371.)

[4] Ralapanawa U, Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J Epidemiol Glob Health. 2021 Jun;11(2):169-177. doi: 10.2991/jegh.k.201217.001. Epub 2021 Jan 7. PMID: 33605111; PMCID: PMC8242111.

[5] WHO. Cardiovascular diseases (CVDs) Fact sheet 11th June 2021.

[6] Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012 May;1821(5):819-25. doi: 10.1016/j.bbalip.2011.10.003. Epub 2011 Oct 8. PMID: 22005032.

[7] Maiti R, Agrawal NK. Atherosclerosis in diabetes mellitus: role of inflammation. Indian J Med Sci. 2007 May;61(5):292-306. PMID: 17478962.

[8] Kempf J, Buysman E, Brixner D. Health Resource Utilization and Direct Costs Associated with Angina for Patients with Coronary Artery Disease in a US Managed Care Setting. Am Health Drug Benefits. 2011 Sep;4(6):353-61. PMID: 25126362; PMCID: PMC4105734.

[9] Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646.

[10] Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019 Aug;234(10):16812-16823. doi: 10.1002/jcp.28350. Epub 2019 Feb 20. PMID: 30790284

[11] Raja S, Mohapatra S, Kumar JS, Rani RJ. Prescription patterns of hypolipidaemic drugs in a tertiary care teaching hospital of southern India. J Clin Diagn Res. 2014 Apr;8(4):HC01-3. doi: 10.7860/JCDR/2014/8010.4206. Epub 2014 Apr 15. PMID: 24959461; PMCID: PMC4064895.

[12] World Health Organization (1985). The rational use of drugs. Report of the conference of experts, Geneva. [http://www.apps.who.int/ medicinedocs/ en/m/abstract/Js17054e/](http://www.apps.who.int/%20medicinedocs/%20en/m/abstract/Js17054e/)

[13] Muir AJ, Sanders LL, Wilkinson WE, Schmader K. Reducing medication regimen complexity: a controlled trial. J Gen Intern Med. 2001;16(2):77-82. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1495168/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/11251757)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Gen+Intern+Med&title=Reducing+medication+regimen+complexity:+a+controlled+trial&author=AJ+Muir&author=LL+Sanders&author=WE+Wilkinson&author=K+Schmader&volume=16&issue=2&publication_year=2001&pages=77-82&pmid=11251757&)] [[Ref list](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935084/#B6)]

[14] George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacotherapy. 2004;38(9):1369-76. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/15266038)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann+Pharmacother&title=Development+and+validation+of+the+medication+regimen+complexity+index&author=J+George&author=YT+Phun&author=MJ+Bailey&author=DC+Kong&author=K+Stewart&volume=38&issue=9&publication_year=2004&pages=1369-1376&pmid=15266038&)] [[Ref list](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935084/#B7)]

[15] Tinoco MS, Groia-Veloso RCS, Santos JNDD, Cruzeiro MGM, Dias BM, Reis AMM. Medication regimen complexity of coronary artery disease patients. Einstein (Sao Paulo). 2021 Mar 15;19:eAO5565. doi: 10.31744/einstein\_journal/2021AO5565. PMID: 33729285; PMCID: PMC7935084

[16] World Health Organization. Introduction to Drug Utilization Research, 2003. ***Introduction to drug utilization research***. <https://apps.who.int/iris/handle/10665/42627>

[17] World Health Organization. Action Programme on Essential Drugs and Vaccines (‎1993)‎. How to investigate drug use in health facilities: Selected drug use indicators. [*https://apps.who.int/iris/handle/10665/60519*](https://apps.who.int/iris/handle/10665/60519).

[18] World Health Organization (‎1993)‎. Drug utilization studies: methods and uses. Edited by M.N.G Dukes. Regional Officer for Pharmaceuticals Europe. [*https://apps.who.int/iris/handle/10665/260517*](https://apps.who.int/iris/handle/10665/260517).

Review of Literature References:

[19] Wade O. Drug utilization studies - the first attempts. Plenary lecture. In: Sjöqvist F, Agenäs I. eds. Drug utilization studies: implications for medical care. Acta Medica Scandinavica, 1984, Suppl. 683:7-9.

[20] Dukes MNG. Development from Crooks to the nineties. In: Auditing Drug Therapy. Approaches towards rationality at reasonable costs. Stockholm, Swedish Pharmaceutical Press, 1992.

[21] Engel A, Siderius P. *The consumption of drugs. Report on a study 1966-1967*. Copenhagen, WHO Regional Office for Europe, 1968 (EURO 3101).

[22] Consumption of drugs. Report on a symposium in Oslo 1969. Copenhagen, WHO Regional Office for Europe, 1970 (EURO 3102).

[23] World Health Organization (‎1993)‎. Drug utilization studies: methods and uses. Edited by M.N.G Dukes. Regional Officer for Pharmaceuticals Europe. <https://apps.who.int/iris/handle/10665/260517>

[24] Stika L et al. Organization of data collection in Czechoslovakia. In: Bergman U et al., eds. Studies in drug utilization. Methods and applications. WHO Regional Office for Europe,Copenhagen, 1979 (WHO Regional Publications European Series No. 8) pp.125-136.

[25] Baksaas Aasen I et al. Drug dose statistics, list of defined daily doses for drugs registered in Norway. Oslo, Norsk Medicinal Depot, 1975.

[26] WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC Classification and DDD Assignment (2020).  [https://www.whocc.no/ filearchive/publications/ 2020\_ guidelines\_ web.pdf](https://www.whocc.no/%20filearchive/publications/%202020_%20guidelines_%20web.pdf).

[27] ATC/DDD classification: drug utilization data constrains in developing countries [2013]. WHO Drug Inf. 2002 16:233-240 [http://apps.who.int/ medicinedocs/pdf/s4951e/s4951e.pdf](http://apps.who.int/%20medicinedocs/pdf/s4951e/s4951e.pdf).

[28] Jain S, Upadhyaya P, Goyal J, et al. (2015). A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines. ***Perspectives in clinical research***6(2): 86–90.

[29] Ather A, Neelkantreddy P, Anand G, et al, (2013). A study on determination of prescription writing errors in outpatient department of medicine in a teaching hospital***. Indian Journal of Pharmacy Practice***. 6(2):21–4.

[30] Mortazavi SA, Hajebi G (2010). An investigation on the nature and extent of occurrence of errors of commission in hospital prescriptions***. Iranian Journal of Pharmaceutical Research*** 83–7.

[31] Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. Circulation. 2016 Apr 19;133(16):1605-20. doi: 10.1161/CIRCULATIONAHA.114.008729. PMID: 27142605.

[32] Shahjehan RD, Bhutta BS. Coronary Artery Disease. [Updated 2022 Feb 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK564304/>

[33] Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss HW. Coronary Artery Calcification: From Mechanism to Molecular Imaging. JACC Cardiovasc Imaging. 2017 May;10(5):582-593. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28473100)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK564304/#article-20009.r7)]

[34] Sicari R, Cortigiani L. The clinical use of stress echocardiography in ischemic heart disease. Cardiovasc Ultrasound. 2017 Mar 21;15(1):7. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361820/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28327159)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK564304/#article-20009.r8)]

[35] P. L. Gross and J. I. Weitz, “New antithrombotic drugs,”Clinical Pharmacology and Therapeutics, vol. 86, no. 2, pp.139–146, 2009.

[36] García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS One. 2016;11(8):e0160046. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973997/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27490468)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK564304/#article-20009.r14)]

[37] Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–16.

[38] Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.Clinical Pharmacokinetics. 2010;49(12):777–98.

[39] Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28(12):1483–94.

[40] Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, et al. Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high ontreatment platelet reactivity depending on diabetes mellitus status. J Thromb Thrombolysis. 2014;37(4):427–34.

[41] R. J. Linhardt: Heparin: structure and activity. Journal of medicinal chemistry 46, 2551-2564 (2003) DOI: 10.1021/jm030176m

[42] J. McLean: The thromboplastic action of cephalin. Am j Physiol 41, 250 (1916)

[43] Dagli-Hernandez C, Zhou Y, Lauschke VM, Genvigir FDV, Hirata TDC, Hirata MH, Hirata RDC. Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts. Pharmacol Rep. 2022 Feb;74(1):47-66. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/34403130)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK430779/#article-55.r2)]

[44] Raddino R, Della Pina P, Gorga E, Caretta G, Madureri A, Dei Cas L. [Indications for statin therapy in patients with acute coronary syndrome of ischemic origin]. G Ital Cardiol (Rome). 2010 Oct;11(10 Suppl 1):78S-83S. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21416832)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK430779/#article-55.r1)]

[45] McIver LA, Siddique MS. Atorvastatin. [Updated 2022 May 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430779/

[46] Elam MB, Majumdar G, Mozhui K, Gerling IC, Vera SR, Fish-Trotter H, Williams RW, Childress RD, Raghow R. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One. 2017;12(8):e0181308. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542661/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28771594)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK564304/#article-20009.r15)]

[47] White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963–70.

[48] AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium) prescribing information. Wilmington: DE; 2003.

[49] McTaggart F. Comparative pharmacology of rosuvastatin. Atherosclerosis. 2003;4:9–14

[50] Morrison RA, Fung H-L: Abstracts of papers presented before the APhA Academy of Pharmaceutical Sciences 10:126, 1980.

[51] Markis JE, Gorlin R, Mills RM, Williams RA,Schweitzer P, Ransil BJ: Sustained effect of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris.Am J Cardiol 43:265-271, 1979.

[52] Thadani U, Darke AC, Fung H-L, Parker JO:Dose response and duration of action of oral isosorbide dinitrate (ISDN) during sustained therapy in angina pectoris. Am J Cardiol 45:478-487, 1980.

[53] Jupalli A, Iqbal AM. Enoxaparin. [Updated 2022 Feb 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539865/

[54] Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1):15-31. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715843/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26780737)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK539865/#article-21136.r4)]

[55] Levesque H, Verdier S, Cailleux N, Elie-Legrand MC, Gancel A, Basuyau JP, Borg JY, Moore N, Courtois H. Low molecular weight heparins and hypoaldosteronism. BMJ. 1990 Jun 02;300(6737):1437-8. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1663122/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/2165831)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK539865/#article-21136.r5)]

[56] Velicki L, Cemerlić-Adić N, Bogdanović D, Mrdanin T. Rectus sheath haematoma: enoxaparin-related complication. Acta Clin Belg. 2013 Mar-Apr;68(2):147-9. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23967729)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK539865/#article-21136.r6)]

[57] Patel S, Singh R, Preuss CV, et al. Warfarin. [Updated 2022 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470313/>

[58] Pourdeyhimi N, Bullard Z. Warfarin-induced skin necrosis. Hosp Pharm. 2014 Dec;49(11):1044-8. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319805/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25673894)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK470313/#article-31294.r8)]

[59] Abutaki FH, Alfaraj D, Alshahrani A, Elsharkawy T. Warfarin-Induced Calciphylaxis in a COVID-19 Patient. Cureus. 2020 Dec 24;12(12):e12249. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767840/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/33391959)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK470313/#article-31294.r9)]

[60] Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990 Aug;40(2):260-90. doi: 10.2165/00003495-199040020-00007. PMID: 2226216.

[61] Kim KH, Kerndt CC, Adnan G, et al. Nitroglycerin. [Updated 2021 Nov 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482382/>

[62] Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1977 Aug;74(8):3203-7. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC431498/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20623)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK482382/#article-25900.r2)]

[63] Thadani U, Lipicky RJ. Short and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther. 1994 Aug;8(4):611-23. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/7848896)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK482382/#article-25900.r3)]

[64] Brown BG, Bolson E, Petersen RB, Pierce CD, Dodge HT. The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response. Circulation. 1981 Dec;64(6):1089-97. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/6794931)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK482382/#article-25900.r4)]

[65] Divakaran S, Loscalzo J. The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics. J Am Coll Cardiol. 2017 Nov 07;70(19):2393-2410. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687289/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29096811)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK482382/#article-25900.r14)]

[66] Drugs and Lactation Database (LactMed) [Internet]. National Library of Medicine (US); Bethesda (MD): 2006. Nitroglycerin. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30000576)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK482382/#article-25900.r15)]

[67] Nash DT, Nash SD. Ranolazine for chronic stable angina. *Lancet* 2008;372:1335–1341 [[PubMed](https://pubmed.ncbi.nlm.nih.gov/18929905)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Ranolazine+for+chronic+stable+angina&author=DT+Nash&author=SD+Nash&volume=372&publication_year=2008&pages=1335-1341&pmid=18929905&)] [[Ref list](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537111/#B9)]

[68] Izumiya Y, Kojima S, Kojima S, Araki S, Usuku H, Matsubara J, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. *Atherosclerosis.*2011;214(2):415–421. doi: 10.1016/j.atherosclerosis.2010.11.032. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/21168844)] [[CrossRef](https://doi.org/10.1016%2Fj.atherosclerosis.2010.11.032" \t "_blank)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&title=Long-term+use+of+oral+nicorandil+stabilizes+coronary+plaque+in+patients+with+stable+angina+pectoris&author=Y+Izumiya&author=S+Kojima&author=S+Kojima&author=S+Araki&author=H+Usuku&volume=214&issue=2&publication_year=2011&pages=415-421&pmid=21168844&doi=10.1016/j.atherosclerosis.2010.11.032&)] [[Ref list](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889547/#CR70)]

[69] Jaraki O, Strauss WE, Francis S, Loscalzo J, Stamler JS. Antiplatelet effects of a novel antianginal agent, nicorandil. *J Cardiovasc Pharmacol.*1994;23(1):24–30. doi: 10.1097/00005344-199401000-00024. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/7511731)] [[CrossRef](https://doi.org/10.1097%2F00005344-199401000-00024" \t "_blank)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Cardiovasc+Pharmacol&title=Antiplatelet+effects+of+a+novel+antianginal+agent,+nicorandil&author=O+Jaraki&author=WE+Strauss&author=S+Francis&author=J+Loscalzo&author=JS+Stamler&volume=23&issue=1&publication_year=1994&pages=24-30&pmid=7511731&doi=10.1097/00005344-199401000-00024&)] [[Ref list](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889547/#CR71)]

[70] Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. *J Cardiovasc Pharmacol.*2005;46(1):63–67. doi: 10.1097/01.fjc.0000162771.00174.a8. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/15965356)] [[CrossRef](https://doi.org/10.1097%2F01.fjc.0000162771.00174.a8" \t "_blank)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Cardiovasc+Pharmacol&title=Effects+of+the+long-term+administration+of+nicorandil+on+vascular+endothelial+function+and+the+progression+of+arteriosclerosis&author=M+Sekiya&author=M+Sato&author=J+Funada&author=T+Ohtani&author=H+Akutsu&volume=46&issue=1&publication_year=2005&pages=63-67&pmid=15965356&doi=10.1097/01.fjc.0000162771.00174.a8&)] [[Ref list](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889547/#CR72)]

[71] Younis NK, Abi-Saleh B, Al Amin F, El Sedawi O, Tayeh C, Bitar F, Arabi M. Ivabradine: A Potential Therapeutic for Children With Refractory SVT. Front Cardiovasc Med. 2021 Aug 3;8:660855. doi: 10.3389/fcvm.2021.660855. PMID: 34414216; PMCID: PMC8368123.

[72] Khan TM, Patel R, Siddiqui AH. Furosemide. [Updated 2022 Jun 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499921/>

[73] Patibandla S, Heaton J, Kyaw H. Spironolactone. [Updated 2022 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554421/>

[74] Fowler SF, Murray KM. Torsemide: a new loop diuretic. Am J Health Syst Pharm. 1995 Aug 15;52(16):1771-80; quiz 1814-5. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8528833)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK559175/#article-89548.r4)]

[75] Singh S, Preuss CV. Carvedilol. [Updated 2022 Jul 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534868/>

[76] David MNV, Shetty M. Digoxin. [Updated 2022 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK556025/>

[77] Knežević T, Gellineo L, Jelaković A, Premužić V, Dika Ž, Laganović M, Jelaković B. Treatment of Hypertension Induced Albuminuria. Curr Pharm Des. 2018;24(37):4404-4412. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30479206)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK430896/#article-17070.r2)]

[78] Hradec J. Pharmacological therapy for chronic heart failure. Vnitr Lek. 2018 Fall;64(9):853-859. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30441998)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK430896/#article-17070.r3)]

[79] Leru PM, Anton VF, Bumbea H. Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen. Allergy Asthma Clin Immunol. 2018;14:69. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201569/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30386386)] [[Reference list](https://www.ncbi.nlm.nih.gov/books/NBK430896/#article-17070.r4)]

[80] Farzam K, Jan A. Beta Blockers. [Updated 2022 Jul 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK532906/>

[81] Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag. 2005;**1**:217–225. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993956/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/17319107)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vasc+Health+Risk+Manag&title=Premature+coronary+artery+disease+in+Indians+and+its+associated+risk+factors&author=M+Sharma&author=NK+Ganguly&volume=1&publication_year=2005&pages=217-225&pmid=17319107&)]

[82] Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. *Circulation* 1999;99:1165–72. [[PubMed](https://pubmed.ncbi.nlm.nih.gov/10069784)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Circulation&title=Sex,+age,+cardiovascular+risk+factors,+and+coronary+heart+disease:+a+prospective+follow-up+study+of+14+786+middle-aged+men+and+women+in+Finland&author=P+Jousilahti&author=E+Vartiainen&author=J+Tuomilehto&author=P+Puska&volume=99&publication_year=1999&pages=1165-72&pmid=10069784&)]

[83] Virtanen M., Heikkilä K., Jokela M., Ferrie J.E., Batty G.D., Vahtera J., Kivimäki M. Long working hours and coronary heart disease: a systematic review and meta-analysis. *Am J Epidemiol.*2012;176:586–596. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458589/)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/22952309)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am+J+Epidemiol&title=Long+working+hours+and+coronary+heart+disease:+a+systematic+review+and+meta-analysis&author=M.+Virtanen&author=K.+Heikkil%C3%A4&author=M.+Jokela&author=J.E.+Ferrie&author=G.D.+Batty&volume=176&publication_year=2012&pages=586-596&pmid=22952309&)]

[84] [Marie-Isabel K Murray](https://www.omicsonline.org/author-profile/marieisabel-k-murray-337072/)[1](https://www.omicsonline.org/open-access/comorbidities-of-coronary-heart-disease-and-the-impact-on-healthcare-usage-and-productivity-loss-in-a-nationallybased-study-2161-1165-1000347-103392.html#a1),[2](https://www.omicsonline.org/open-access/comorbidities-of-coronary-heart-disease-and-the-impact-on-healthcare-usage-and-productivity-loss-in-a-nationallybased-study-2161-1165-1000347-103392.html#a2)[\*](https://www.omicsonline.org/open-access/comorbidities-of-coronary-heart-disease-and-the-impact-on-healthcare-usage-and-productivity-loss-in-a-nationallybased-study-2161-1165-1000347-103392.html#corr337072), [Inna N Thalmann](https://www.omicsonline.org/author-profile/inna-n-thalmann-337074/)[2](https://www.omicsonline.org/open-access/comorbidities-of-coronary-heart-disease-and-the-impact-on-healthcare-usage-and-productivity-loss-in-a-nationallybased-study-2161-1165-1000347-103392.html#a2), [Elias A Mossialos](https://www.omicsonline.org/author-profile/elias-a-mossialos-337076/)[2](https://www.omicsonline.org/open-access/comorbidities-of-coronary-heart-disease-and-the-impact-on-healthcare-usage-and-productivity-loss-in-a-nationallybased-study-2161-1165-1000347-103392.html#a2) and [Andreas M Zeiher](https://www.omicsonline.org/author-profile/andreas-m-zeiher-337077/)[1](https://www.omicsonline.org/open-access/comorbidities-of-coronary-heart-disease-and-the-impact-on-healthcare-usage-and-productivity-loss-in-a-nationallybased-study-2161-1165-1000347-103392.html#a1)Comorbidities of Coronary Heart Disease and the Impact on Healthcare Usage and Productivity Loss in a Nationally-Based Stud**y**10.4172/2161-1165.1000347. Epidemiology (Sunnyvale) 2018, Vol 8(3): 347

[85] Degrauwe S, Pilgrim T, Aminian A, et al. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017;4(2):e000651.[**Article**](https://doi.org/10.1136%2Fopenhrt-2017-000651)[**Google Scholar**](http://scholar.google.com/scholar_lookup?&title=Dual%20antiplatelet%20therapy%20for%20secondary%20prevention%20of%20coronary%20artery%20disease&journal=Open%20Heart&volume=4&issue=2&publication_year=2017&author=Degrauwe%2CS&author=Pilgrim%2CT&author=Aminian%2CA)

[86] Lee LV. Anticoagulants in coronary artery disease. Cardiol Clin. 2008 Nov;26(4):615-28. doi: 10.1016/j.ccl.2008.07.002. PMID: 18929235.

[87] Lim SY. Role of statins in coronary artery disease. Chonnam Med J. 2013 Apr;49(1):1-6. doi: 10.4068/cmj.2013.49.1.1. Epub 2013 Apr 25. PMID: 23678470; PMCID: PMC3651980.

[88] Wei J, Wu T, Yang Q, Chen M, Ni J, Huang D. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol. 2011 Jan 7;146(1):4-12. doi: 10.1016/j.ijcard.2010.05.019. Epub 2010 Jun 16. PMID: 20557963.

[89] Zhao F, Chaugai S, Chen P, Wang Y, Wang DW. Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Ther. 2014 Dec;32(6):283-96. doi: 10.1111/1755-5922.12097. PMID: 25319832.

[90] Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis. 2018 Jul 4;9(11):199-207. doi: 10.1177/2040622318784556. PMID: 30364460; PMCID: PMC6196638.

[91] Casu G, Merella P. Diuretic Therapy in Heart Failure - Current Approaches. Eur Cardiol. 2015 Jul;10(1):42-47. doi: 10.15420/ecr.2015.10.01.42. PMID: 30310422; PMCID: PMC6159465.

[92] Spencer AP. Digoxin in heart failure. Crit Care Nurs Clin North Am. 2003 Dec;15(4):447-52. doi: 10.1016/s0899-5885(02)00091-6. PMID: 14717389.

[93] Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003;63(16):1697-741. doi: 10.2165/00003495-200363160-00006. PMID: 12904089.

[94] Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992 Nov 14;340(8829):1173-8. doi: 10.1016/0140-6736(92)92889-n. PMID: 1359258.

[95] Strauss MH, Hall AS, Narkiewicz K. The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. Cardiovasc Drugs Ther. 2021 Sep 17. doi: 10.1007/s10557-021-07248-1. Epub ahead of print. PMID: 34533690.

[96] Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019 Jul 30;18(1):96. doi: 10.1186/s12933-019-0900-7. PMID: 31362743; PMCID: PMC6668189.

[97] Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia. 1996 Nov;39(11):1345-50. doi: 10.1007/s001250050581. Erratum in: Diabetologia 1997 Mar;40(3):366. PMID: 8933003.

[98] Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011 Mar 2;305(9):913-22. doi: 10.1001/jama.2011.250. Erratum in: JAMA. 2011 May 11;305(18):1862. PMID: 21364140; PMCID: PMC4313888.